Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials

This article was originally published in PharmAsia News

Executive Summary

Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad

You may also be interested in...



China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules

SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January

China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules

SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January

U.S. Mulls Registration Fees For Foreign Drug Manufacturers

In light of recent safety concerns about foreign-manufactured pharmaceutical products, members of the U.S. Congress are considering whether to introduce registration fees for foreign drug manufacturers exporting products to the U.S

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel